Sweden · Delayed Price · Currency is SEK SynAct Pharma AB Earnings Call Transcripts
Fiscal Year 2026
-
Key clinical data from three programs are expected in the next two quarters, driving a shift to active business development. The lead RA program targets early, high-activity patients with a novel, non-immunosuppressive therapy, while host-directed therapies for respiratory infections address major unmet needs. Strong financials and a dual-track strategy support broad partnering opportunities.
Fiscal Year 2025
-
Resomelagon is advancing in phase IIB trials for rheumatoid arthritis and host-directed viral infection therapies, with major data readouts and a dengue study expected next year. The approach targets immune modulation, aiming to improve outcomes and reduce side effects.
-
Lead RA study is on track for year-end data, with new PMR and dengue programs broadening the pipeline. Recent capital raises and a credit facility secure funding through 2026, supporting clinical and business development efforts targeting licensing or acquisition deals.
Fiscal Year 2024
-
A refocused strategy prioritizes the ADVANCE phase II study in newly diagnosed, high-activity RA patients, aiming for data by end of next year and subsequent partnering. Resomelagon offers a novel, immune-preserving approach with strong efficacy in the right subgroup, addressing a large unmet need in RA and attracting significant industry interest.